目的 探讨不同剂型紫杉醇联合卡铂对复发性卵巢癌患者的成本-效果。方法 选取滁州市第一人民医院2016年5月—2018年5月收治的60例复发性卵巢癌患者为研究对象，随机将其分为对照组与观察组，每组30例。对照组患者第1日给予175 mg/m²的传统紫杉醇注射液，加入到5%葡萄糖注射液500 mL中，静脉滴注3 h，给药前给予地塞米松预处理。次日采用5 AUC卡铂注射液，加入5%葡萄糖注射液500 mL，静脉滴注2 h。观察组患者给予175 mg/m²注射用紫杉醇脂质体，加入5%葡萄糖注射液500 mL，静脉滴注3 h；5 AUC卡铂注射液加入到5%葡萄糖注射液500 mL中，静脉滴注2 h。21 d为1个周期，两组共治疗6个周期。结果 治疗后，观察组临床总有效率为66.67%，与对照组的60.00%相比，差异不具有统计学意义。治疗期间，观察组患者的毒副反应率为20.00%，显著低于对照组46.67%，两组比较差异具有统计学意义（P<0.05）。观察组的化疗药物使用费用高于对照组，毒副反应治疗药物低于对照组，两组比较差异有统计学意义（P<0.05）。观察组的增量成本-效果比（△C/△E）为7 234.65，即增加1个效果单位，观察组需多花7 234.65元。结论 复发性卵巢癌患者采用传统紫杉醇联合卡铂治疗具有较高的疗效及经济性，值得临床推广应用。

Objective To investigate the cost-effectiveness of paclitaxel combined with carboplatin in patients with recurrent ovarian cancer. Methods Patients (60 cases) with recurrent ovarian cancer in the First People's Hospital of Chuzhou from May 2016 to May 2018 were selected as the study subjects, and randomly divided into control group and observation group, with 30 patients in each group. Patients in the control group were given Paclitaxel Injection of 175 mg/m² on the first day, added into 5% glucose injection 500 mL, intravenous infusion for 3 h, and dexamethasone pretreatment before administration. The next day, 5 AUC Carboplatin Injection was added into 5% glucose injection 500 mL, and intravenous infusion was given for 2 hours. Patients in the observation group were given Paclitaxel Liposome for injection 175 mg/m², 500 mL 5% glucose injection was added, and intravenous infusion was administered for 3 h. 5 AUC Carboplatin Injection was added into 5% glucose injection 500 mL, and intravenous infusion was administered for 2 h. 21 d as one cycle, two groups were treated for 6 cycles. Results After treatment, the total clinical effective rate in the observation group was 66.67%, which was not statistically significant compared with 60.00% in the control group. During the treatment, the toxic and side reaction rate in the observation group was 20.00%, which was significantly lower than 46.67% in the control group, the difference between two groups was statistically significant (P<0.05). The use cost of chemotherapy drugs in the observation group was higher than that in the control group, and the toxic and side reaction drugs were lower than that in the control group, the difference between two groups was statistically significant (P<0.05). The △C/△E of the observation group was 7 234.65, that is to say, an additional effect unit was needed, the observation group needed to spend 7 234.65 yuan more. Conclusion Traditional Paclitaxel Injection combined with carboplatin in treatment of recurrent ovarian cancer has high efficacy and economy, which is worthy of clinical application.

R979.1

安徽省卫生和计划生育委员会科研计划项目（2016QK037）